RxDoctor Payments Data

Stephen Oehme, MD

Family Medicine · Rock Hill, SCNPI 1861493496

Payments from drug & device makers

$3,379in general payments, 2019–2025

Across 32 payments — averaging $105.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$452
  • Bayer$360
  • GSK$327
  • Inspire Medical Systems, Inc.$139
  • Intuitive Surgical$135
  • plus $821 from 8 others

What the payments were for

  • Food & beverage$3,373100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,379 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$220,612
Medicare patients
689
Services billed
3,292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide114$179,215
EliquisApixaban141$152,769
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$57,980
Tresiba Flextouch U-200Insulin Degludec37$45,211
RybelsusSemaglutide36$41,732
TrulicityDulaglutide25$36,208
JanuviaSitagliptin Phosphate23$34,095
FarxigaDapagliflozin Propanediol23$30,661
XareltoRivaroxaban31$26,101
MounjaroTirzepatide19$23,261
LinzessLinaclotide32$22,870
JardianceEmpagliflozin22$21,468
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$16,910
WegovySemaglutide11$16,077
MyrbetriqMirabegron14$13,391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$452$237,024161 claims
GSKTrelegy Ellipta, Breo Ellipta$327$65,31595 claims
Lilly USA, LLCTrulicity, Mounjaro$110$59,47044 claims
AstraZenecaFarxiga, Symbicort, Brilinta$1,146$47,13668 claims
MerckJanuvia$101$34,09523 claims
AbbVieLinzess$125$22,87032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Rock Hill

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →